Information Provided By: 
Fly News Breaks for April 22, 2016
SRPT
Apr 22, 2016 | 14:13 EDT
Piper Jaffray analyst Edward Tenthoff said the FDA's publishing of voting questions ahead of the committee meeting to review Sarepta's eteplirsen was "a surprise move." There is a chance the meeting could be more positive than expected, but accelerated approval of the drug by the May 26 PDUFA date is unlikely, Tenthoff tells investors. The firm keeps a Neutral and $15 price target on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
